A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs MP 0250 (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Molecular Partners AG
- 29 May 2017 Status changed from not yet recruiting to recruiting.
- 27 Apr 2017 Status changed from planning to not yet recruiting.
- 27 Oct 2016 According to a Molecular Partners AG media release, first safety data are expected in 2017 and efficacy data in 2018 from this trial.